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This Paper is dedicated to our close friend and mentor Professor Peter Black who died suddenly in January 2010. Peter was
instrumental in the conception and design of this study. His death is a huge loss to the COPD research community and to us
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Background: Susceptibility to Chronic Obstructive Pulmonary Disease (COPD) has a genetic
component. We undertook a study to determine if a genetic variant of the gene encoding
the cyclooxygenase-2 gene influences the likelihood of developing COPD.
Methods: In a case control study the frequency of a single nucleotide polymorphism in the
promoter region of the cyclooxygenase-2 gene (-765 G/ C) was determined in 205 subjects
with COPD, 171 chronic smokers with normal lung function (resistant smokers) and 95 healthy
blood donors using the polymerase chain reaction and restriction enzyme fragment length
polymorphism.
Results: The frequency of the C allele of the -765 cyclooxygenase-2 polymorphism was higher
in resistant smokers (24.6%) compared with subjects with COPD (14.4%, OR Z 1.98, 95%tive pulmonary disease; -765 G/C, guanine to cytosine substitution at position -765 of the cyclo-
E2, prostaglandin E2; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; FEV1,
, forced vital capacity; ATS, American Thoracic Society; PCR, polymerase chain reaction; RFLP,
lymorphism; DNA, deoxyribonucleic acid; SNP, single nucleotide polymorphism; TGF-b1, transforming
viation; SOD, superoxide dismutase.
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Cyclooxygenase-2-765C promoter polymorphism 507CI Z 1.28e3.06, p Z 0.003) and blood donors (14.7%, OR Z 1.97, 95% CI Z 1.14e3.41,
p Z 0.03).
Conclusions: The -765C allele, which has been shown to be associated with decreased
promoter activity of the cyclooxygenase-2 gene, is more common in resistant smokers. This
raises the possibility that decreased activity of cyclooxygenase-2 may protect smokers against
the development of COPD.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is charac-
terized by progressive airflow obstruction that is largely
irreversible.1 This is thought to be due both to changes in
the small airways and to emphysema which involves
destruction of the alveolar wall. Family studies suggest that
there is a genetic predisposition to COPD2 and a number of
genetic polymorphisms have been reported to be associ-
ated with COPD, although a smaller number have been
replicated in different populations.3
Cyclooxgenase-2 catalyzes the conversion of arachidonic
acid to prostaglandin H2 which is the precursor of other
prostaglandins and thromboxanes.4 Unlike cyclooxygenase-1
which is expressed constitutively in almost all tissues,
cyclooxygenase-2 is induced in response to a number of
cytokines and growth factors.4 There is a number of reasons
for suspecting that cyclooxygenase-2 may have a role in the
pathogenesis of COPD. Xaubet et al. found increased immu-
nohistochemical staining for cyclooxygenase-2 in lung tissue
compared with control subjects.5 They also demonstrated
increased expression of cyclooxygenase-2 mRNA in COPD
tissue. Taha and colleagues performed immunostaining for
cyclooxygenase-2 in cells from induced sputum frompatients
with COPD and control subjects and found a higher propor-
tion of cells that stained positively in the patients with
COPD.6 Cyclooxygenase-2 could contribute to the develop-
ment of COPD through the effects of prostaglandin E2 (PGE2)
to promote the secretion of matrix metalloproteinases.
Matrix Metalloproteinase-2 (MMP-2) and Matrix Metal-
loproteinase-9 (MMP-9) have been implicated as having a role
in the tissue damage that occurs in emphysema. NS398which
is a cyclooxygenase-2 inhibitorwas shown to inhibit secretion
of Pro MMP-2 and Pro MMP-9 by a cultured prostate cancer
cell line.7 Explanations for COPD have focused on tissue
destruction leading to emphysema but it is also possible that
defective tissue repair could contribute to the development
of COPD.8 Prostaglandin E2 inhibits the proliferation of
pulmonary fibroblasts,9 a mechanism by which the cyclo-
oxygenase-2 could inhibit tissue repair in COPD.
Papafili and her colleagues were the first to describe the
-765 G/C polymorphism in the promoter region of the
cyclooxygenase-2 gene.10 The -765C allele was found to be
associated with lower promoter activity. Subsequently
Cipollone et al. found that that the -765C allele was asso-
ciated with a lower prevalence of myocardial infarction and
stroke and there was decreased immunohistochemical
staining for cyclooxygenase-2 in carotid endarterectomy
specimens from patients with the -765C allele.11 When
monocytes from patients with the -765 GG genotype were
stimulated with lipopolysaccharide there was increasedformation of cyclooxygenase-2 and PGE2 compared with
individuals carrying the -765C allele.12
We have compared the frequency of the -765C allele in
patients with COPD, in resistant smokers (who have not
developedCOPDdespite a smoking history of 15 pack years or
more), and in a group of healthy blood donors to determine if
this allele protects against development of COPD.Methods
Subjects
Group 1. COPD (smokers with impaired lung function
consistent with COPD)
We recruited subjects of European descent (i.e. all four
grandparents were European) with COPD who had been
previouslydiagnosedbya specialist physicianandwhomet the
following criteria: they were over 40 years of age with
aminimum fifteen pack year smoking history with a FEV1/FVC
ratio (Forced Expiratory Volume in One Second/Forced Vital
Capacity) <70% and FEV1 as a percentage of predicted <80%
(EuropeanCoal and Steel Community referencevalues). COPD
subjects were identified by pre-bronchodilator spirometry,
performed to American Thoracic Society (ATS) guidelines, on
admission to Auckland City Hospital (New Zealand) with
infective exacerbation of COPD or following attendance at
a hospital outpatient clinic. Identified patients were then
re-assessed, using Bronchodilator Reversibility Testing (pre-
bronchodilator and post-bronchodilator spirometry) based on
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines, while in a stable condition and after
withholding their usual COPD medications for the following
periods: short-acting bronchodilators 6 h, long acting bron-
chodilators and inhaled corticosteroids for 12 h. Post-bron-
chodilator spirometry was performed 15e20 min after
administration of the bronchodilator (salbutamol, 400mg).
Subjects with a >20% reversibility in FEV1 or with FEV1/
FVC> 70% in response to inhaled bronchodilator therapywere
excluded. No subjects had been on oral corticosteroids,
inhaled long acting anticholinergic inhalers or oral broncho-
dilating agents in the 6 week period prior to testing. Those
withahistoryofanyof the followingwereexcluded:childhood
or early adulthood asthma; prior evidence of a >20% revers-
ibility in FEV1 in response to inhaled bronchodilator therapy;
symptoms of breathlessness before 40 years of age, or past
lung surgery. COPD subjects were also excluded if they
answered yes to the question “Have you ever been diagnosed
with bronchiectasis?”, or were diagnosed as having bronchi-
ectasis in their hospital records, or on clinical or radiological
grounds.
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We also recruited from the same community (from social
clubs for the elderly living in the same city suburbs as the
COPD cases) a cohort of resistant smokers of European
descent (all four grandparents were European), who vol-
unteered to be studied and who met the following
criteria: they were over 40 years of age; had a minimum
15 pack years smoking history; and an FEV1/FVC ratio
between 70% and 90% and FEV1 as a percentage of pre-
dicted >80%.
Utilising questions from the ATS Respiratory Question-
naire, occupational exposure to dusts and fumes was
recorded from the COPD subjects and resistant smokers.
Using a PCR based method,13 we genotyped the COPD
subjects and the resistant smokers for the a1-antitrypsin
mutations (S and Z variants) and excluded those with the ZZ
or SZ genotype. Those with the MZ genotype were included
and made up 5% of both the COPD and resistant smoker
cohorts.
Group 3. blood donors
We also recruited 95 blood donors of European descent (all
four grandparents were European) whose recruitment was
unrelated to smoking status and who were healthy with no
known respiratory illnesses.
The study was approved by the Auckland Ethics
Committee and all subjects gave informed written consent.
Polymerase chain reaction (PCR) and restriction enzyme
fragment length polymorphism (RFLP) were used to analyze
the genotype of the polymorphism.
DNA extraction
Genomic DNA was extracted from whole blood using DNAzol
(Gibco Life Technologies) following standard protocols
given by the manufacturer.
PCR amplification
Reaction mixtures (25 mL) were prepared, each containing
about 20 ng DNA, 1 U Taq polymerase (Life Technologies),
and a final concentration of 1 Buffer, 0.2 mM dNTPs (Life
Technologies), 5 mM of each Primer (from Gibco BRL life
Technologies), and 1.5 mM MgCl2. The primer sequences
were based on the study of Papafili et al.10 The forward
primer (CF-8) was CCGCTTCCTTTGTCCATCAG and the
reverse primer (CR-7) was GGCTGTATATCTGCTCTATATGC.
The PCR product size was 306 bp. Using a PTC-100
Programmable Thermal Controller (from MJ Research Inc,
Biolab Scientific Ltd), PCR was performed with an initial
denaturation at 94 C for 3 min. This was followed by 40
cycles, with denaturation at 94 C for 1 min, annealing at
55 C for 1 min, elongation at 72 C for 45 s, followed by
a final elongation of 5 min at 72 C. An amplification check
was carried out using electrophoresis. The gel was prepared
using 25 mL of agarose gel (Gibco BRL Life Technologies) in
0.5% TAE buffer containing 0.25 mL ethidium bromide. 4 mL
of the amplification product and 3 mL of the following
mixture, 95% formamide, 10 mM EDTA, 0.05% bromophenol
blue, 0.05% xylene cyanol, were added to each well.Electrophoresis was performed in 200 mL of 0.5% TAE buffer
with 2.5 mL ethidium bromide, with a voltage of 90 mV for
10 min. Positive and negative control template DNAs were
included in each PCR run.
Restriction enzyme digestion
The variants (-765 G/C) were detected by AciI (New
England Biolabs) restriction endonuclease which selectively
digests -765 G allele into 188 bp and 118 bp products.
The reaction mixture was 4 mL of the amplification
product digested with 2U AciI, in a mixture containing 1 mL
NE Buffer3 (New England Biolabs) in 10 mL reactions. The
reaction mixture was incubated at 37 C for 2 h. Restriction
enzyme-digested PCR products were subjected to electro-
phoresis in a 2.5% agarose gel (Seakem: FMC, Rockland, ME)
at 70 mV for 2 h in 200 ml of TBE buffer. Using ultraviolet
transillumination after ethidium bromide staining, the
products were visualised, and the size of the product was
determined using 123 bp ladder. A positive control and
a negative control were included in each digestion.
Statistical analysis
The demographic characteristics of the COPD and resistant
smokers were compared using Fisher’s Exact Test for
gender and student’s t-test for unrelated groups for the
continuous normally distributed variables. Genotype
frequencies were compared with HardyeWeinberg equi-
librium within each cohort. Allele and genotype frequen-
cies were compared between cohorts using the
Mantel-Haenszel Chi square test to generate Odd’s Ratios
with 95% confidence limits. Logistic regression was used to
provide the odds of COPD/resistant smoking for each
genotype after adjusting for age and pack years. Analyses
were conducted using procedures of SAS (SAS Institute Inc,
version 9.1 for Windows). All tests were two tailed taking
P < 0.05 as significant. Evidence for population stratifica-
tion was sought using Structure (v2.1).13
Results
Thecharacteristics of the 205 subjectswithCOPDand the171
resistant smokers are summarized in Table 1. The subjects
with COPD did not differ significantly from the resistant
smokers in the proportion who were male (p Z 0.23) or in
smoking history (p Z 0.15), but they were younger
(p < 0.0001). We undertook a logistic regression controlling
for age, gender and smoking history. This did not affect the
findings. The resistant smokers had near normal lung func-
tion while the subjects with COPD had a mean FEV1% pre-
dicted of 38.6% and FEV1/FVC of 0.48. In the healthy blood
donors 62% were men and their mean (SD) age was 49.8 (9.5)
years. 36% had never smoked. Lung function data were not
available in this group but none had a diagnosis of COPD.
We found no evidence of population stratification using
19 unlinked SNPs from different genes (mean c2 Z 4.2,
p Z 0.23).
The distribution of genotypes and the allele frequency
are shown in Table 2. The frequency of the C allele was
similar in the subjects with COPD (14.4%) and the blood
Table 1 Characteristics of subjects with COPD and resistant smokers.
COPD (n Z 205) Resistant Smokers (n Z 171)
Male (%) 113 (54.9%) 108 (62.85%)
Mean Age (years) (SD) 66.1 (10.4) 59.3a (11.4)
Mean Pack Years (SD) 43.8 (22.4) 47.8 (24.7)
Mean FEV1 (litres) (SD) 1.02 (0.52) 2.84 (0.69)
Mean FEV1 %predicted (SD) 38.6 (15.8) 96.3 (10.6)
FEV1/FVC (SD) 0.48 (0.13) 0.81 (0.08)
a The resistant smokers were significantly younger than the subjects with COPD (p < 0.0001). In the COPD group, FEV1 and FVC values
were post-bronchodilator spirometry measurements. There was no significant difference between the two groups for gender or smoking
history.
Cyclooxygenase-2-765C promoter polymorphism 509donors (14.7%) but was more frequent in the resistant
smokers (24.6%). There was no significant deviation of
genotype frequency from HardyeWeinberg equilibrium.
The Odd’s Ratio for the resistant smokers having the C
allele was 1.98 (95% CI 1.28e3.06, p Z 0.003) compared
with the subjects with COPD, and 1.97 (1.14e3.41,
p Z 0.03) compared with the blood donors. There was no
difference between the subjects with COPD and the blood
donors (OR Z 0.99, 95% CI 0.57e1.72, p Z 0.93).
In the logistic regression which adjusted for age, gender
and smoking history the Odds Ratio for the resistant
smokers having the C allele compared with the subjects
with COPD was 2.21 (95% CI 1.39e3.52, p Z 0.0008).Discussion
We have demonstrated that the -765C promoter poly-
morphism in the cyclooxygenase-2 gene is more frequent in
resistant smokers than it is in smokers with COPD and
healthy blood donors. This polymorphism is associated with
reduced expression of cyclooxygenase-2.10 This suggests
that a decrease in cyclooxygenase-2 may protect against
the development of the COPD in smokers. There are several
reasons why a decrease in cyclooxygenase-2 may be bene-
ficial. MMP-2 and MMP-9 have elastolytic activity and there
are reports of increased expression of MMP-2 and MMP-9 in
lung tissue from individuals with COPD.14,15 This is relevant
because COPD is characterized by damage to the elastic
fibers in the lung.16 NS398, which is a cyclooxygenase-2
inhibitor, decreases the secretion of Pro MMP-2 and Pro
MMP-9 from prostate cancer cells,8 while rofecoxib, which
is also a selective cyclooxygenase-2 inhibitor, decreases the
expression of MMP-2 and MMP-9 in splenic tumours in
mice.17 It is conceivable that reduced expression of cyclo-
oxygenase-2 is associated with lower levels of MMP-2 andTable 2 Distribution of allele frequency and distribution of ge
donor controls.
C allele (%) G allele
COPD (n Z 205) 14.4% 85.6%
Resistant Smokers (n Z 171) 24.6% 75.4%
Blood Donors (n Z 95) 14.7% 85.3%
There was no significant difference between the subjects with COPD an
likely to have the C allele than the subjects with COPD (OR Z 1.98, 9
1.14e3.41; p Z 0.03).MMP-9 in the lung and that this could protect against the
development of emphysema. COPD, however, may not just
be a consequence of increased tissue destruction. Fibro-
blasts from the lungs of patients with COPD proliferate
more slowly than control fibroblasts18 and it is possible that
defective tissue repair contributes to the development of
COPD. Because PGE2 inhibits the proliferation of pulmonary
fibroblasts,9 the upregulation of cyclooxygenase-2 that has
been reported in COPD lung may inhibit repair,6 whereas
the reduced expression of cyclooxygenase-2 observed with
the -765C variant may promote repair. We have previously
reported that a single nucleotide polymorphism in codon 10
of the transforming growth factor beta 1 (TGF-b1) gene,
which is associated with increased production of TGF-b1,
protects against the development of COPD.19 TGF-b1 both
inhibits the secretion of MMP-9 by monocytes20 and
promotes the proliferation of fibroblasts.21 This raises the
possibility that -765C polymorphism in the cyclooxygenase-
2 gene and the codon 10 polymorphism in the TGF-b1 gene
may exert protective effects in similar ways. Indeed, this
was the reason that led us to examine the relationship
between the -765C polymorphism and COPD. We further
believe that the reduction in -765C polymorphism increases
cyclooxygenase-2 due to the biological plausibility of the
association that we have reported. Recently, a study on
superoxide dismutase (SOD) variants indicates that the
variant 213Gly of the SOD3 gene may confer a degree of
resistance in some smokers to the development of COPD.22
With genetic association studies there is the concern
that confounding may occur because the cases and controls
are not well matched. The background frequency of an
allele can vary in different ethnic groups and problems can
arise if population stratification occurs i.e. if the ethnic
background of the cases and controls differ.23,24 Because of
this concern we only included subjects who were European
in the study. In addition we found no evidence ofnotypes in subjects with COPD, resistant smokers and blood
(%) CC CG GG
6 (2.9%) 47 (22.9%) 152 (74.1%)
14 (8.1%) 56 (32.7%) 101 (59.1%)
3 (3.2%) 22 (23.2%) 70 (73.7%)
d the blood donors. The resistant smokers were significantly more
5% CI 1.28e3.06; p Z 0.003) or blood donors (OR Z 1.97, 95% CI
510 L. Wu et al.population stratification using 19 unlinked SNPs from
unrelated genes. It is also reassuring that the frequency of
the C allele in the blood donors and in the subjects with
COPD is very similar to that reported in other studies of this
polymorphism in European populations.10,25 We note,
however, that we did not have available spirometry data
from the blood donors, thus it is possible that there may
have been some early-stage COPD patients in this group.
The patients with COPD and the resistant smokers were
similar in terms of gender and smoking history, the resistant
smokers were younger. The adjusted and unadjusted odds
ratios were similar and the results remained statistically
significant. We recognize that these results may be
affected by unknown factors, and in particular a lack of
mechanistic data, but nevertheless they do raise the
possibility that treatment with non-steroidal anti-inflam-
matory drugs may beneficially influence the progression of
COPD.Acknowledgements
The authors thank Mr. Gregory D Gamble for his excellent
assistance with statistics analysis and thank A/Professor
James Paxton for his helping with the manuscript.
Conflict of interest statement
All authors confirm that none has any conflicts of interest,
financial or personal, relating to thefindings in this publication.
References
1. Celli BR, MacNee W. Standards for the diagnosis and treatment
of patients with COPD: a summary of the ATS/ERS position
paper. Eur Respir J 2004;23:932e46.
2. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic
obstructive pulmonary disease. Eur Respir J 1997;10:1380e91.
3. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ,
Kwiatowski D, Kwiatowski D, Laird N, Sylvia JS, Sparrow D,
Speizer FE, Weiss ST, Silverman EK. Attampted replication of
reported chronic obstructive pulmonary disease candidate
gene associations. Am J Respir Cell Mol Biol 2005;33:71e8.
4. Mitchell JA, Warner TD. COX isoforms in the cardiovascular
system: understanding the activities of non-steroidal anti-
inflammatory drugs. Nat Rev Drug Discov 2006;5:75e86.
5. Xaubet A, Roca-Ferrer J, Pujols L, Ramirez J, Mullol J, Marin-
Arguedas A, Torrego A, Ginferrer JM, Picado C. Cyclooxygenase-2
is upregulated in lung parenchyma of chronic obstructive pulmo-
nary disease and down regulated in idiopathic pulmonary fibrosis.
Sarcoidosis Vasc Diffuse Lung Dis 2004;21:35e42.
6. Taha R, Olivenstein R, Utsumi T, Ernst P, Barnes PJ, Rodger IW,
Giad A. Prostaglandin H synthase 2 expression in airway cells
from patients with asthma and chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2000;161:636e40.
7. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ,
Patierno SR. Inhibitors of prostaglandin synthesis inhibit human
prostate tumor cell invasiveness and reduce the release of
matrix metalloprotienases. Cancer Res 2000;60:4629e37.
8. Rennard S. Chronic obstructive pulmonary disease. Linking
outcomes and pathobiology of disease modification. Proc Am
Thorac Soc 2006;3:276e80.
9. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M.
Prostaglandin E2 synthesis and suppression of fibroblastproliferation by alveolar epithelial cells is cyclooxygenase-2-
dependent. Am J Respir Cell Mol Biol 2002;27:752e8.
10. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP,
Humphries SE, Laurent GJ. Common promoter variant in
cyclooxygenase-2 represses gene expression: evidence of
a role in acute phase inflammatory response. Arterioscler
Thromb Vasc Biol 2002;22:1631e6.
11. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A,
Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M,
Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S,
Virdis A, Ciabattoni G, Notabartolo A, Cuccurullo F, Mezetti A.
A polymorphism in the cyclooxygenase-2 gene as an inherited
protective factor against myocardial infarction and stroke.
JAMA 2004;291:2221e8.
12. Sandford AJ, et al. 1-antitrypsin genotypes and the acute
phase response to open heart surgery. Am J Respir Crit Care
Med 1999;159:1624e8.
13. Pritchard JK, Stephens M, Donnelly P. Inference of population
structure from multilocus genotype data. Genetics 2000;155:
945e59.
14. Ohnishi K, et al. Matrix metalloproteinase-mediated extracel-
lular matrix protein degradation in human pulmonary emphy-
sema. Lab Invest 1998;78:1077e87.
15. Segura-Valdez L, et al. Upregulation of gelatinases A and B,
collagenases 1 and 2, and increased parenchymal cell death in
COPD. Chest 2000;117:684e94.
16. Finlay GA, O’Donnell MD, O’Connor CM, Hayes JP,
FitzGerald MX. Elastin and collagen remodelling in emphy-
sema. A scanning electron microscopy study. Am J Pathol 1996;
149:1405e15.
17. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E,
Evans JF, Wolfe MM. Inhibition of cyclooxygenase-2 by rofe-
coxib attenuates the growth and metastatic potential of
colorectal carcinoma in mice. Cancer Res 2003;63:586e92.
18. Holz O, Zuhlke I, Jaksztat E, et al. Lung fibroblasts from
patients with emphysema show a reduced proliferation rate in
culture. Eur Respir J 2004;24:575e9.
19. Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R,
McLean L, Black PN. Transforming growth factoreb1 genotype
and susceptibility to chronic obstructive pulmonary disease.
Thorax 2004;59:126e9.
20. Ogawa K, Chen F, Kuang C, Chen Y. Suppression of matrix
metalloproteinase-9 transcription by transforming growth
factor-beta is mediated by a nuclear factor-kappaB site.
Biochem J 2004;381(Pt 2):413e22.
21. Hetzel M, Bachem M, Anders D, Trischler G, Faehling M.
Different effects of growth factors on proliferation and matrix
production of normal and fibrotic human lung fibroblasts. Lung
2005;183:225e37.
22. Young RP, Hopkins R, Black PN, Eddy C, Wu L, Gamble GD,
Mills GD, Garrett JE, Eaton TE, Rees MI. Functional variants of
antioxidant genes in smokers with COPD and in those with
normal lung function. Thorax 2006 May;61(5):394e9. Epub
2006 Feb 7. PubMed PMID: 16467073; PubMed Central PMCID:
PMC2111196.
23. Cardon LR, Palmer LJ. Population stratification and spurious
allelic association. Lancet 2003;361:598e604.
24. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-anal-
yses on suspected chronic obstructive pulmonary disease
genes: a summary of 20 years’ research. Am J Respir Crit Care
Med 2009 Oct 1;180(7):618e31. Epub 2009 Jul 16. Review.
Erratum in: Am J Respir Crit Care Med. 2010 Apr 1;181(7):765.
PubMed PMID:19608716.
25. Ulrich CM, Whitton J, Yu J-H, Sibert J, Sparks R, Potter JD,
Bigler J. PTGS2 (Cox-2) -765G>C promoter variant reduces the
risk of colorectal adenoma among nonusers of nonsteroidal
anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev
2005;14:616e9.
